Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LEGN
stocks logo

LEGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
318.45M
+70.73%
0.095
-32.1%
332.02M
+70.22%
-0.040
-92.59%
367.32M
+44.01%
0.070
-110.29%
Estimates Revision
The market is revising Downward the revenue expectations for Legend Biotech Corporation (LEGN) for FY2025, with the revenue forecasts being adjusted by -1.44% over the past three months. During the same period, the stock price has changed by -20.52%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.44%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+27.78%
In Past 3 Month
Stock Price
Go Down
down Image
-20.52%
In Past 3 Month
Wall Street analysts forecast LEGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEGN is 73.75 USD with a low forecast of 60.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast LEGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEGN is 73.75 USD with a low forecast of 60.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.810
sliders
Low
60.00
Averages
73.75
High
90.00
Current: 27.810
sliders
Low
60.00
Averages
73.75
High
90.00
H.C. Wainwright
Mitchell Kapoor
Buy
maintain
$60
2025-11-26
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$60
2025-11-26
maintain
Buy
Reason
H.C. Wainwright analyst Mitchell Kapoor says private company Kelonia Therapeutics reported early in vivo CAR-T data that showed no detectable cancer cells in all three treated patients and "robust" CAR-T expansion without lymphodepletion. The data pressured valuations across the B-cell maturation antigen space, the analyst tells investors in a research note. However, H.C. Wainwright believes Kelonia's dataset remains "extremely small" and "far from" clinically comparable to a commercial-stage CAR-T. It sees little readthrough to Legend Biotech's Carvykti and reiterates a Buy rating on the shares with a $60 price target. Legend's competitive fears are overdone, the firm contends.
Cantor Fitzgerald
Overweight
maintain
$66 -> $75
2025-11-13
Reason
Cantor Fitzgerald
Price Target
$66 -> $75
2025-11-13
maintain
Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Legend Biotech to $75 from $66 and keeps an Overweight rating on the shares. Legend reported Q3 earnings, with sales for Carvykti reaching $524M in Q3, marking another record quarter for a CAR T-cell therapy, the analyst tells investors in a research note. The firm says the outlook for BCMA-directed CAR T therapy is robust, driven by earlier adoption, Carvykti's overall survival benefit, and broader outpatient and community adoption.
Barclays
Gena Wang
Overweight
downgrade
$94 -> $90
2025-11-13
Reason
Barclays
Gena Wang
Price Target
$94 -> $90
2025-11-13
downgrade
Overweight
Reason
Barclays analyst Gena Wang lowered the firm's price target on Legend Biotech to $90 from $94 and keeps an Overweight rating on the shares following the Q3 report.
H.C. Wainwright
Buy
downgrade
$75 -> $60
2025-10-17
Reason
H.C. Wainwright
Price Target
$75 -> $60
2025-10-17
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Legend Biotech to $60 from $75 and keeps a Buy rating on the shares. Johnson & Johnson (JNJ) reported a Q3 sales beat for Carvykti but Legend Biotech shares had a muted reaction, the analyst tells investors in a research note. The firm believes this reflects Carvykti growth already being priced into the shares.
Cantor Fitzgerald
Overweight
initiated
$55 -> $66
2025-08-27
Reason
Cantor Fitzgerald
Price Target
$55 -> $66
2025-08-27
initiated
Overweight
Reason
Cantor Fitzgerald assumed coverage of Legend Biotech with an Overweight rating and price target of $66, up from $55. The firm sees 88% potential upside from the current price. The company's Carvykti has "rapidly become" the most successful CAR T-cell therapy on the market. the analyst tells investors in a research note. Cantor believes Carvykti is positioned o be a multi-billion-dollar franchise.
JPMorgan
Jessica Fye
maintain
$77 -> $78
2025-08-25
Reason
JPMorgan
Jessica Fye
Price Target
$77 -> $78
2025-08-25
maintain
Reason
JPMorgan analyst Jessica Fye raised the firm's price target on Legend Biotech to $78 from $77 and keeps an Overweight rating on the shares. The firm updated the company's model.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Legend Biotech Corp (LEGN.O) is 123.55, compared to its 5-year average forward P/E of -14.20. For a more detailed relative valuation and DCF analysis to assess Legend Biotech Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-14.20
Current PE
123.55
Overvalued PE
36.65
Undervalued PE
-65.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-18.90
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.43
Undervalued EV/EBITDA
-46.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
28.55
Current PS
0.00
Overvalued PS
50.12
Undervalued PS
6.99
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LEGN News & Events

Events Timeline

(ET)
2025-11-12
07:08:12
Legend Biotech anticipates funding to last past 2026
select
2025-11-12
07:07:35
Legend Biotech announces Q3 adjusted EPS of 5 cents, falling short of consensus estimate of 12 cents.
select
2025-09-05 (ET)
2025-09-05
10:36:21
Legend Biotech reportedly negotiating for international listing, according to Bloomberg.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
11-27Newsfilter
Legend Biotech Awarded 2025 Foreign Investor of the Year, Investing €165 Million to Expand Cell Therapy Operations
  • Foreign Investor Award: Legend Biotech was recognized as the Foreign Investor of the Year at the 2025 Flanders International Business Awards, highlighting its long-term commitment and economic contributions in Belgium, thereby reinforcing Flanders' status as a global biotech hub.
  • Major Investment Expansion: The company announced a €165 million joint investment with Johnson & Johnson to expand its state-of-the-art facility in Ghent, positioning it as one of Europe's largest CAR-T manufacturing centers, which is expected to significantly enhance its clinical and commercial supply capabilities across the EMEA region.
  • Employee Growth: Since commencing operations in Ghent in 2022, Legend Biotech's workforce has surged from just 2 to over 1,000 employees representing 66 nationalities, demonstrating the company's robust growth momentum within the local biotech ecosystem.
  • Strategic Partnerships: Through collaborations with FIT and VOKA, as well as partnerships with leading research institutions like VIB and Ghent University, Legend Biotech has established a unique environment in Flanders where science and industry mutually reinforce each other, further enhancing the company's innovation capabilities and market competitiveness.
[object Object]
Preview
7.5
11-27Globenewswire
Legend Biotech Awarded 2025 Foreign Investor of the Year, Investing €165 Million in Cell Therapy Expansion
  • Foreign Investor Award: Legend Biotech was honored with the Foreign Investor of the Year award at the 2025 Flanders International Business Awards, underscoring its long-term commitment and economic contributions that reinforce Flanders' status as a global biotech hub.
  • Significant Investment Expansion: The company announced a €165 million joint investment with Johnson & Johnson to expand its state-of-the-art facility at Tech Lane Ghent Science Park, solidifying its leadership in CAR-T manufacturing in Europe and enhancing clinical and commercial supply capabilities.
  • Employee Growth: Since commencing operations in Ghent in 2022, Legend Biotech's workforce has surged from just 2 to over 1,000 employees representing 66 nationalities, reflecting the company's robust growth within the local biotech ecosystem.
  • Strategic Partnerships: By collaborating with FIT and VOKA, along with leading research institutions like VIB and Ghent University, Legend Biotech emphasizes the synergy between science and industry, further driving its innovative capabilities in cell therapy.
[object Object]
Preview
8.0
11-24NASDAQ.COM
Noteworthy LEGN Put and Call Options Set for January 2026

  • Put Contract Overview: The $25.00 put contract for LEGN has a bid of 5 cents, allowing investors to buy shares at a cost basis of $24.95, which is a 14% discount from the current price of $28.97. There is a 72% chance the contract may expire worthless, offering a potential 0.20% return on cash commitment.

  • Call Contract Overview: The $35.00 call contract has a bid of 10 cents, and if shares are purchased at $28.97 and the call is sold, it could yield a total return of 21.16% if exercised by January 2026. There is a 71% chance this contract may also expire worthless, providing a potential 0.35% extra return.

  • Volatility Insights: The implied volatility for the put contract is 73%, while the call contract has an implied volatility of 78%. In contrast, the actual trailing twelve-month volatility is calculated at 46%.

  • YieldBoost Concept: Both the put and call contracts offer a "YieldBoost," with the put providing a 1.38% annualized return if it expires worthless, and the call offering a 2.38% annualized return under the same condition.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Legend Biotech Corp (LEGN) stock price today?

The current price of LEGN is 27.81 USD — it has increased 0.22 % in the last trading day.

arrow icon

What is Legend Biotech Corp (LEGN)'s business?

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

arrow icon

What is the price predicton of LEGN Stock?

Wall Street analysts forecast LEGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEGN is 73.75 USD with a low forecast of 60.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Legend Biotech Corp (LEGN)'s revenue for the last quarter?

Legend Biotech Corp revenue for the last quarter amounts to 272.33M USD, increased 69.99 % YoY.

arrow icon

What is Legend Biotech Corp (LEGN)'s earnings per share (EPS) for the last quarter?

Legend Biotech Corp. EPS for the last quarter amounts to -0.11 USD, decreased -67.65 % YoY.

arrow icon

What changes have occurred in the market's expectations for Legend Biotech Corp (LEGN)'s fundamentals?

The market is revising Downward the revenue expectations for Legend Biotech Corporation (LEGN) for FY2025, with the revenue forecasts being adjusted by -1.44% over the past three months. During the same period, the stock price has changed by -20.52%.
arrow icon

How many employees does Legend Biotech Corp (LEGN). have?

Legend Biotech Corp (LEGN) has 2600 emplpoyees as of December 05 2025.

arrow icon

What is Legend Biotech Corp (LEGN) market cap?

Today LEGN has the market capitalization of 5.13B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free